Will We Ever Use Angiotensin Receptor Neprilysin Inhibition (ARNi) for the Treatment of Hypertension?

Blood Pressure - United Kingdom
doi 10.1080/08037051.2019.1584975
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

When Will We Ever Learn?

Annales Universitatis Mariae Curie-Sklodowska, sectio FF, Philologia
2017English

Metabolic Actions Could Confound Advantageous Effects of Combined Angiotensin II Receptor and Neprilysin Inhibition

Hypertension
Internal Medicine
2011English

Will We Ever Stop Using Fossil Fuels?

Journal of Economic Perspectives
EconomicsEconometrics
2016English

Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2017English

Orthodontic Retention Regimes: Will We Ever Have the Answer?

Evidence-Based Dentistry
Dentistry
2006English

Effects of the Angiotensin‐Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta‐Analysis

Journal of the American Heart Association
Cardiovascular MedicineCardiology
2019English

Will We Ever Have Paris? Canada's Climate Change Policy and Federalism 3.0

Alberta Law Review
2018English

Neprilysin Inhibition for Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial

British Journal of Pharmacology
Pharmacology
2019English

The Relationship Between Governments and Independent Regulatory Agencies: Will We Ever Get It Right?

Alberta Law Review
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy